These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
468 related articles for article (PubMed ID: 30689009)
21. Atrial fibrillation and coronary artery disease: a review on the optimal use of oral anticoagulants. Bocchino PP; Angelini F; Toso E Rev Cardiovasc Med; 2021 Sep; 22(3):635-648. PubMed ID: 34565066 [TBL] [Abstract][Full Text] [Related]
22. Antithrombotic therapy in patients with atrial fibrillation and acute coronary syndrome and / or undergoing percutaneous coronary intervention. Mihajlovic M; Marinkovic M; Kozieł M; Mujovic N; Lip GYH; Potpara TS Kardiol Pol; 2020 Jun; 78(6):512-519. PubMed ID: 32543800 [TBL] [Abstract][Full Text] [Related]
23. Current status of antithrombotic therapy and in-hospital outcomes in patients with atrial fibrillation undergoing percutaneous coronary intervention in Germany. Zeymer U; Toelg R; Wienbergen H; Hobbach HP; Cuneo A; Bekeredjian R; Ritter O; Hailer B; Hertting K; Hennersdorf M; Scholtz W; Lanzer P; Mudra H; Schwefer M; Schwimmbeck PL; Liebetrau C; Thiele H; Claas C; Riemer T; Zahn R Herz; 2023 Mar; 48(2):134-140. PubMed ID: 35243515 [TBL] [Abstract][Full Text] [Related]
24. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions. Cheng JW; Barillari G J Clin Pharm Ther; 2014 Apr; 39(2):118-35. PubMed ID: 24383983 [TBL] [Abstract][Full Text] [Related]
25. Intracranial haemorrhages vs. stent thromboses with direct oral anticoagulant plus single antiplatelet agent or triple antithrombotic therapy: a meta-analysis of randomized trials in atrial fibrillation and percutaneous coronary intervention/acute coronary syndrome patients. Galli M; Andreotti F; Porto I; Crea F Europace; 2020 Apr; 22(4):538-546. PubMed ID: 31942971 [TBL] [Abstract][Full Text] [Related]
26. Is There a Role for Triple Therapy After ACS? Bhogal S; Alkhouli M; White CJ; Bailey S; Mamas M; Haddad E; Paul TK Curr Cardiol Rep; 2022 Mar; 24(3):191-200. PubMed ID: 35112242 [TBL] [Abstract][Full Text] [Related]
27. Antithrombotic treatment in patients with atrial fibrillation and acute coronary syndromes: results of the European Heart Rhythm Association survey. Lane DA; Dagres N; Dan GA; García Seara J; Iliodromitis K; Lenarczyk R; Lip GYH; Mansourati J; Marín F; Scherr D; Potpara TS Europace; 2019 Jul; 21(7):1116-1125. PubMed ID: 30874724 [TBL] [Abstract][Full Text] [Related]
28. Antithrombotic therapies in Canadian atrial fibrillation patients with concomitant coronary artery disease: Insights from the CONNECT AF + PCI-II program. Chow JK; Bagai A; Tan MK; Har BJ; Yip AMC; Paniagua M; Elbarouni B; Bainey KR; Paradis JM; Maranda R; Cantor WJ; Eisenberg MJ; Dery JP; Madan M; Cieza T; Matteau A; Roth S; Lavi S; Glanz A; Gao D; Tahiliani R; Welsh RC; Kim HH; Robinson SD; Daneault B; Chong AY; Le May MR; Ahooja V; Gregoire JC; Nadeau PL; Laksman Z; Heilbron B; Yung D; Minhas K; Bourgeois R; Overgaard CB; Bonakdar H; Logsetty G; Lavoie AJ; De LaRochelliere R; Mansour S; Spindler C; Yan AT; Goodman SG; J Cardiol; 2023 Aug; 82(2):153-161. PubMed ID: 36931433 [TBL] [Abstract][Full Text] [Related]
29. Contemporary Antithrombotic Treatment in Patients with Non-valvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: Rationale and Design of the Greek AntiPlatElet Atrial Fibrillation (GRAPE-AF) Registry. Xanthopoulou I; Dragona VM; Davlouros P; Tsioufis C; Iliodromitis E; Alexopoulos D; Cardiovasc Drugs Ther; 2018 Apr; 32(2):191-196. PubMed ID: 29679301 [TBL] [Abstract][Full Text] [Related]
30. An analysis of antithrombotic therapy in elderly patients with atrial fibrillation undergoing percutaneous coronary interventions. Zhou J; Wang X; Yu J; Wu Y; Li X; Xie X; Zhang X; Cheng D; Yang B Clin Exp Pharmacol Physiol; 2023 Jul; 50(7):583-593. PubMed ID: 37057840 [TBL] [Abstract][Full Text] [Related]
31. Apixaban versus PhenpRocoumon: Oral AntiCoagulation plus antiplatelet tHerapy in patients with Acute Coronary Syndrome and Atrial Fibrillation (APPROACH-ACS-AF): Rationale and design of the prospective randomized parallel-group, open-label, blinded-endpoint, superiority, multicenter-trial of a triple therapy versus a dual therapy in patients with Atrial Fibrillation and Acute Coronary Syndrome undergoing coronary stenting. Riesinger L; Strobl C; Leistner DM; Gori T; Akin I; Mehr M; Kellnar A; Mahabadi AA; Bogossian H; Block M; Edelmann F; Sarafoff N; Sibbing D; Ince H; Rassaf T; Mansmann U; Mehilli J; Kääb S; Hausleiter J; Massberg S; Wakili R Int J Cardiol Heart Vasc; 2021 Aug; 35():100810. PubMed ID: 34258380 [TBL] [Abstract][Full Text] [Related]
32. NOAC-Based Sual Therapy Versus Warfarin-Based Triple Therapy After Percutaneous Coronary Intervention or Acute Coronary Syndrome in Patients With Atrial Fibrillation: A Systematic Review and Meta-Analysis. Dahal K; Mosleh W; Almnajam M; Khaddr M; Adeel MY; Vashist A; Robinson P; Azrin M; Lee J Cardiovasc Revasc Med; 2020 Oct; 21(10):1202-1208. PubMed ID: 32173329 [TBL] [Abstract][Full Text] [Related]
34. Dual antiplatelet therapy versus oral anticoagulation plus dual antiplatelet therapy in patients with atrial fibrillation and low-to-moderate thromboembolic risk undergoing coronary stenting: design of the MUSICA-2 randomized trial. Sambola A; Montoro JB; Del Blanco BG; Llavero N; Barrabés JA; Alfonso F; Bueno H; Cequier A; Serra A; Zueco J; Sabaté M; Rodríguez-Leor O; García-Dorado D Am Heart J; 2013 Oct; 166(4):669-75. PubMed ID: 24093846 [TBL] [Abstract][Full Text] [Related]
35. Clinical Outcomes of Antithrombotic Strategies for Patients with Atrial Fibrillation After Percutaneous Coronary Intervention. Gao X; Ge Z; Kong X; Wang Z; Zuo G; Wang F; Chen S; Zhang J Int Heart J; 2019 May; 60(3):546-553. PubMed ID: 31105152 [TBL] [Abstract][Full Text] [Related]
36. Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial. Vranckx P; Valgimigli M; Eckardt L; Tijssen J; Lewalter T; Gargiulo G; Batushkin V; Campo G; Lysak Z; Vakaliuk I; Milewski K; Laeis P; Reimitz PE; Smolnik R; Zierhut W; Goette A Lancet; 2019 Oct; 394(10206):1335-1343. PubMed ID: 31492505 [TBL] [Abstract][Full Text] [Related]
37. Is there a Role for Oral Triple Therapy in Patients with Acute Coronary Syndromes Without Atrial Fibrillation? Spinthakis N; Farag M; Akhtar Z; Gorog DA Curr Vasc Pharmacol; 2018; 16(5):427-436. PubMed ID: 29345587 [TBL] [Abstract][Full Text] [Related]
38. Managing antithrombotic therapy in patients with both atrial fibrillation and coronary heart disease. Thompson PL; Verheugt FW Clin Ther; 2014 Sep; 36(9):1176-81. PubMed ID: 25234549 [TBL] [Abstract][Full Text] [Related]
39. [Oral anticoagulation and antiplatelet therapy in patients with atrial fibrillation after coronary interventions]. Schäfer A; Bauersachs J Herz; 2019 Jun; 44(4):365-378. PubMed ID: 31087108 [TBL] [Abstract][Full Text] [Related]
40. New-onset atrial fibrillation after recent coronary stenting: Warfarin or non-vitamin K-antagonist oral anticoagulants to be added to aspirin and clopidogrel? A viewpoint. Rubboli A; Agewall S; Huber K; Lip GY Int J Cardiol; 2015 Oct; 196():133-8. PubMed ID: 26093527 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]